Market Place
Sourcing Support
ImaginAb advances two solid tumour radiopharmaceutical therapy candidates
19 May 2023 //
PHARMABIZ
ImaginAb Advances Two Solid Tumor RPT Candidates Towards Clinical Development
18 May 2023 //
PR NEWSWIRE
ImaginAb and Quibim partner to revolutionize immune status diagnosis
02 May 2023 //
PR NEWSWIRE
ImaginAb Executes License Agreement for CD8 ImmunoPET Technology
12 Apr 2023 //
PR NEWSWIRE
ImaginAb Executes License and Supply Agreement with TriSalus
22 Nov 2022 //
PRNEWSWIRE
ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology
15 Nov 2022 //
PRNEWSWIRE
ImaginAb and Cyclotek Enter into Agreement for CD8 ImmunoPET Agent in Australia
17 Oct 2022 //
PRNEWSWIRE
ImaginAb expands Pipeline to include Radiopharmaceutical Therapies
04 Oct 2022 //
PRNEWSWIRE
ImaginAb, Roche have entered trial supply agreement for atezolizumab
08 Jun 2022 //
PRNEWSWIRE
ImaginAb signs supply agreement with Invicro for CD8 ImmunoPET imaging agent
12 May 2022 //
PRNEWSWIRE
BriaCell and ImaginAb Collaborate to Evaluate Immunotherapy Imaging Technology
19 Aug 2021 //
GLOBENEWSWIRE
Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology
30 Jun 2021 //
BUSINESSWIRE
ImaginAb signs license agreement with Pfizer to supply 89Zr CD8 Immuno
08 Jan 2021 //
PHARMABIZ
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET
07 Jan 2021 //
PRNEWSWIRE
Clarity Pharmaceuticals and ImaginAb to Collaborate on New Cancer Targets
21 Jul 2020 //
PRNASIA
ImaginAb & ARTMS Announce Strategic Partnership for Innovative Mfg of 89Zr CD8
07 Apr 2020 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.